A PYMNTS Company

Solving the Wrong Problem The Preliminary Report on the EC Pharmaceutical Sector Inquiry: What Have We Really Learned?

BY | December 22, 2015

This article is part of a Chronicle. See more from this Chronicle Kent Bernard, Feb 23, 2009 You could posit several fairly obvious reasons for the perceived lack of new…

This article is part of a Chronicle. See more from this Chronicle

Kent Bernard, Feb 23, 2009

You could posit several fairly obvious reasons for the perceived lack of new innovative drugs in the European Union: Low reimbursement levels for innovative medicines and insistent tolerance for diversion/parallel would certainly be on the list. And reference pricing often makes generics much more expensive in the EU than in the United States, while at the same time making research into new branded drugs

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 142.93.75.231

Please verify email or join us to access premium content!